CD38

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.